预约演示
更新于：2025-08-27
Oseltamivir Phosphate
磷酸奥司他韦
更新于：2025-08-27
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1999-09-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H31N2O8P |
InChIKeyPGZUMBJQJWIWGJ-ONAKXNSWSA-N |
CAS号204255-11-8 |
关联
331
项与 磷酸奥司他韦 相关的临床试验CTR20252188
磷酸奥司他韦颗粒在空腹及餐后条件下的人体生物等效性试验
CTR20252118
磷酸奥司他韦颗粒在健康受试者中的单剂量、空腹、随机、开放、两周期、两交叉生物等效性研究
CTR20251446
磷酸奥司他韦干混悬剂（6 mg/mL）单次给药餐后状态下在健康受试者中的生物等效性试验
100 项与 磷酸奥司他韦 相关的临床结果
登录后查看更多信息
100 项与 磷酸奥司他韦 相关的转化医学
登录后查看更多信息
100 项与 磷酸奥司他韦 相关的专利（医药）
登录后查看更多信息
6,035
项与 磷酸奥司他韦 相关的文献（医药）2025-12-31Emerging Microbes & Infections
Influenza H5Nx viruses are susceptible to MEK1/2 inhibition by zapnometinib
Article
作者: Beer, Martin ; Brunotte, Linda ; Kumar, Sriram ; Ludwig, Stephan ; Caliskan, Duygu Merve ; Oberberg, Nicole ; Schreiber, André ; Rodner, Franziska ; Ambrosy, Benjamin
Highly pathogenic avian influenza A viruses (HPAIV) pose a significant threat to both animal and human health. These viruses have the potential to cause severe respiratory and systemic infections in birds and several mammalian species. The recent global outbreak of the H5N1 clade 2.3.4.4b spread in wild and domestic birds is now considered to be a panzoonosis. Spillover events in dairy cattle farms in the U.S. have highlighted the urgent need for effective antiviral therapies, especially in view of human infections. This study investigates the selective MEK1/2 inhibitor zapnometinib (ZMN) as a potential antiviral agent against HPAIVs. Our in vitro experiments demonstrate that ZMN significantly impairs viral replication across multiple HPAIV strains, including H5N1 clade 2.3.4.4b in cell lines and primary bronchial epithelial cells. The mechanism of action is based on the nuclear retention of newly produced viral ribonucleoprotein complexes (vRNP), when the MEK/ERK/RSK1 kinase cascade is inhibited. We furthermore could show, that ZMN not only acts antiviral in a standalone treatment but has synergistic potential when used in combination with direct-acting antivirals like oseltamivir or baloxavir. Therefore, ZMN treatment offers a promising strategy for future antiviral development.
2025-12-31Emerging Microbes & Infections
Neuraminidase reassortment and oseltamivir resistance in clade 2.3.4.4b A(H5N1) viruses circulating among Canadian poultry, 2024
Article
作者: Joseph, Tomy ; Berhane, Yohannes ; Raj, Sugandha ; Lung, Oliver ; Pama, Lemarie ; Alkie, Tamiru N. ; Hisanaga, Tamiko ; Bastien, Nathalie ; Signore, Anthony V. ; Ranadheera, Charlene ; Ayilara, Ifeoluwa ; Erdelyan, Cassidy N. G.
We report the detection of a clade 2.3.4.4b A(H5N1) reassortant virus with a neuraminidase surface protein derived from a North American lineage low-pathogenic avian influenza virus. This virus caused a widespread and ongoing outbreak across 45 poultry farms in British Columbia, Canada. Isolates from 8 farms reveal a mutation in the neuraminidase protein (H275Y) that is exceptionally rare among clade 2.3.4.4b viruses (present in 0.045% of publicly available clade 2.3.4.4b isolates). NA-H275Y is a well-known marker of resistance to the neuraminidase inhibitor oseltamivir. We demonstrate that this substitution maintains its resistance phenotype on the genetic background of H5N1 clade 2.3.4.4b viruses.
2025-12-01PHYTOCHEMISTRY
Potential anti-H1N1 schitriterpenoids from Kadsura japonica L. vines
Article
作者: Sung, Ping-Jyun ; Chen, Jih-Jung ; Huang, Hung-Tse ; Li, Tsung-Lin ; Chao, Chih-Hua ; Lin, Yu-Chi ; Lo, I-Wen ; Chiou, Chun-Tang ; Zhang, Li-Jie ; Liaw, Chia-Ching
Lethal contagious pathogens wreak havoc on human life and the global economy, especially influenza and other respiratory pathogens, as exemplified by the enduring impact of COVID-19. This study reports that triterpenoids isolated from the stems of medicinal plants Kadsura japonica L. (Schisandraceae), which exhibit potent anti-viral activity against collected influenza viruses. Collectively, four undescribed schitriterpenoids named kadsujanonols J-M (1-4) along with five previously reported, schincarin D (5), ananosin E (6), changnanic acid (7), longipedlactone A (8), and schiglansin S (9), were isolated and identified. Their chemical structures were determined using 1H-, 13C-, and 2D-NMR spectra in conjunction with spectroscopic analyses, such as UV, IR, ECD, and HRESIMS. These schitriterpenoids were then subjected to antiviral examination against the collected H1N1 influenza viruses, in which several, changnanic acid (7) in particular, unveiled excellent anti-H1N1 activity compared to Tamiflu.
100 项与 磷酸奥司他韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 甲型流感病毒感染 | 美国 | 1999-10-27 | |
| 流感病毒感染 | 瑞士 | 1999-09-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肥胖 | 临床2期 | 美国 | 2010-07-01 | |
| 慢性呼吸道疾病 | 临床1期 | 中国 | 2022-05-27 | |
| 糖尿病 | 临床1期 | 中国 | 2022-05-27 | |
| 心脏病 | 临床1期 | 中国 | 2022-05-27 | |
| 肾功能不全 | 临床1期 | 中国 | 2022-05-27 | |
| 乙型流感病毒感染 | 临床1期 | 中国 | 2021-09-06 | |
| 终末期肾脏病 | 临床1期 | 新西兰 | 2001-10-01 | |
| 病态肥胖 | 临床阶段不明 | 加拿大 | 2009-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 222 | 5-day postexposure prophylaxis with oseltamivir | 積範遞選鹹衊餘獵簾餘(鏇鹽觸積網鏇糧鏇鹽齋) = 襯淵選夢繭觸鏇築顧膚 鏇鹽網窪蓋襯夢餘齋顧 (顧衊夢簾構簾壓夢醖壓 ) | - | 2020-08-01 | ||
N/A | 558 | Oseltamivir 75 mg | 顧積膚顧願遞繭鬱淵糧(製窪餘獵顧餘範淵獵獵) = 遞繭壓艱簾廠蓋願鹽範 壓蓋醖鏇膚鹽膚醖夢積 (窪觸鏇襯廠鹽構襯簾鹹 ) | - | 2020-05-23 | ||
Placebo | 顧積膚顧願遞繭鬱淵糧(製窪餘獵顧餘範淵獵獵) = 壓鏇網積衊積繭醖遞齋 壓蓋醖鏇膚鹽膚醖夢積 (窪觸鏇襯廠鹽構襯簾鹹 ) | ||||||
临床3期 | 228 | (conventional-dose) | 衊膚憲窪簾構鏇醖範鹽(鹽構膚齋淵築壓憲鬱鹹) = 醖繭憲網簾壓淵淵鹽觸 艱廠獵窪製選鬱網蓋蓋 (鑰襯遞醖壓壓鬱遞淵襯 ) | 积极 | 2019-12-01 | ||
(double-dose) | 衊膚憲窪簾構鏇醖範鹽(鹽構膚齋淵築壓憲鬱鹹) = 廠選積醖繭鹽窪醖鹽網 艱廠獵窪製選鬱網蓋蓋 (鑰襯遞醖壓壓鬱遞淵襯 ) | ||||||
临床2期 | 10 | Danirixin 15mg + oseltamivir 75mg | 積製齋齋淵餘蓋襯鬱鹹(膚網膚膚製顧艱壓餘鹹) = 簾構顧廠糧願夢艱壓鏇 繭憲築衊壓艱獵襯製鏇 (築艱網築膚鬱網餘構淵, 2.95 ~ 5.71) | - | 2019-04-01 | ||
Danirixin 50mg + oseltamivir 75mg | 積製齋齋淵餘蓋襯鬱鹹(膚網膚膚製顧艱壓餘鹹) = 鬱範夢簾廠觸遞顧餘艱 繭憲築衊壓艱獵襯製鏇 (築艱網築膚鬱網餘構淵, 2.71 ~ 5.25) | ||||||
N/A | 716 | (Oseltamivir) | 鏇襯遞衊鬱夢鏇鹹艱蓋 = 鹽鹽夢鹹獵鑰製繭製構 繭齋襯夢顧襯夢淵糧獵 (網繭鹹壓積齋鏇艱構廠, 獵鬱餘簾糧艱窪製蓋簾 ~ 遞選繭醖願窪選衊鹽顧) 更多 | - | 2019-02-05 | ||
Placebo (Placebo) | 鏇襯遞衊鬱夢鏇鹹艱蓋 = 範衊遞選獵蓋鹽壓鹹鑰 繭齋襯夢顧襯夢淵糧獵 (網繭鹹壓積齋鏇艱構廠, 願繭膚遞願鹹膚壓願糧 ~ 窪艱鹹壓願顧糧構餘願) 更多 | ||||||
临床3期 | 228 | placebo+oseltamivir (Conventional Dose) | 夢蓋願齋願鹽獵遞夢構 = 顧鏇鏇醖簾願齋製積願 選顧積鏇觸製糧鏇繭壓 (鏇艱觸膚窪構觸餘齋窪, 鏇遞簾構艱糧鑰艱餘膚 ~ 積襯夢遞襯齋願簾壓鑰) 更多 | - | 2018-07-12 | ||
placebo+oseltamivir (Double Dose) | 夢蓋願齋願鹽獵遞夢構 = 艱鑰淵選窪艱夢糧網願 選顧積鏇觸製糧鏇繭壓 (鏇艱觸膚窪構觸餘齋窪, 網構製淵窪範鹹願繭構 ~ 齋齋選繭鏇衊襯糧獵糧) 更多 | ||||||
临床4期 | 180 | (Oseltamivir) | 觸築觸淵網構製餘襯壓(繭繭鏇鹹鹽築襯構獵簾) = 顧衊構遞獵壓積簾艱構 鏇遞簾糧願遞壓醖構淵 (蓋蓋繭鬱觸遞餘願簾鬱, 0.8) 更多 | - | 2018-06-20 | ||
(Peramivir) | 觸築觸淵網構製餘襯壓(繭繭鏇鹹鹽築襯構獵簾) = 夢顧鹹構築襯鏇積觸糧 鏇遞簾糧願遞壓醖構淵 (蓋蓋繭鬱觸遞餘願簾鬱, 1.3) 更多 | ||||||
临床1/2期 | 21 | 襯蓋鹹淵窪糧範簾繭獵(餘繭範襯顧廠齋遞願淵) = 獵遞鹽網範餘餘鹽廠簾 夢襯鬱糧遞顧簾衊顧蓋 (醖鹽壓衊願餘簾醖鏇遞, 510) 更多 | - | 2016-12-06 | |||
临床1期 | 8 | (Oseltamivir: 6 to 12 Years) | 蓋範積壓鏇構餘鹽繭觸(憲鬱簾簾積齋積蓋壓艱) = 積獵鹽繭鬱築廠蓋鏇鹽 鏇淵獵膚糧糧餘範衊網 更多 | - | 2016-08-24 | ||
(Oseltamivir: 3 to 5 Years) | 蓋範積壓鏇構餘鹽繭觸(憲鬱簾簾積齋積蓋壓艱) = 齋築鹹襯顧壓鹹顧願範 鏇淵獵膚糧糧餘範衊網 (餘衊廠網鹹鏇積選蓋構, 46.3) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用